An upper limit of gonadotropin dose in patients undergoing ART should be advocated

S. Friedler, S. Meltzer, B. Saar-Ryss, J. Rabinson, T. Lazer, G. Liberty

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Aim: As no upper limit of the daily dose of gonadotropins (DD GN) used for controlled ovarian hyperstimulation (COH) in patients undergoing assisted reproductive technology (ART) has been established, we aimed to evaluate the efficacy of using different DD GN in terms of live-birth achievement. Methods: Data of patients treated at a single university medical center during the same period was analyzed retrospectively. Four groups were analyzed according to the DD GN administered: group I (“high dose”): >225– ≤ 375 IU; Group II (“Very high dose”): 376–450 IU; group III (“extremely high dose”): 451–600 IU. Normo-responders treated with DD GN ≤250 IU served as control (C). Variables included were DD GN, total GN dose/cycle, age, FSH, BMI, gravidity, parity, cycle number, IVF/ICSI, infertility diagnosis treatment protocol and outcome parameters. Results: The analysis of 1394 treatment cycles of 943 patients indicated that DD and total dose of GN correlated negatively with the number of oocytes, implantation, clinical pregnancy and live-birth rate (25.9%, 14.6%, 11.4% and 4.7% in groups C, I, II and III, respectively) The logistic regression analysis indicated that the adjusted odds ratios for LBR correlated inversely with the DD administered–independently from age, baseline FSH, BMI and previous failed cycles. Conclusions: Increasing the daily dose of GN to doses higher than 450 IU or a total dose of 3000 IU/cycle is at least questionable if not harmful.

Original languageEnglish
Pages (from-to)965-969
Number of pages5
JournalGynecological Endocrinology
Volume32
Issue number12
DOIs
StatePublished - 1 Dec 2016

Keywords

  • COH
  • IVF
  • gonadotropin dose
  • live-birth rate
  • poor ovarian responder

Fingerprint

Dive into the research topics of 'An upper limit of gonadotropin dose in patients undergoing ART should be advocated'. Together they form a unique fingerprint.

Cite this